Christopher Hite, EVP and Chairman of Partnering at Royalty Pharma plc (NASDAQ:RPRX), filed a Form 4 on November 6, 2026, disclosing an acquisition of Class A Ordinary Shares on November 4, 2026, in connection with the settlement of Equity Performance Awards.

Key Highlights

  • Acquisition: Hite acquired 7,122 Class A Ordinary Shares at a price of $0 on November 4, 2026, indirectly through SCH Investment Partners LLC.
  • Transaction type: The acquisition was coded "A" and described as an exempt acquisition under Rule 16b-3 in connection with the settlement of Equity Performance Awards.
  • Post-transaction holdings: Following the transaction, 277,523 Class A Ordinary Shares are beneficially owned indirectly by Hite through SCH Investment Partners LLC, plus a separate direct holding of 23,200 Class A Ordinary Shares.
  • Additional indirect interests: Family vehicles controlled by Hite hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares.
  • Vesting conditions: According to the filing, the Class E Ordinary Shares of Royalty Pharma Holdings Ltd "are subject to vesting conditions."

Hite's Equity Performance Award Settlement at Royalty Pharma

According to the Form 4 filed with the SEC on November 6, 2026, Christopher Hite, who serves as EVP and Chairman of Partnering at Royalty Pharma plc, received 7,122 Class A Ordinary Shares on November 4, 2026, at a price of $0 per share. The filing indicates this acquisition was exempt under Rule 16b-3 and occurred in connection with the settlement of Equity Performance Awards. The shares were acquired indirectly through SCH Investment Partners LLC.

Following this transaction, the filing reports that Hite beneficially owns 277,523 Class A Ordinary Shares indirectly through SCH Investment Partners LLC, as well as 23,200 Class A Ordinary Shares held directly. The Form 4 was signed by Sean Weisberg as Attorney-in-Fact for Christopher Hite on November 6, 2026.

The filing also discloses that family vehicles controlled by Hite hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 866,410 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd that are exchangeable into 1,238,789 Class A Ordinary Shares. The filing notes that the Class E Ordinary Shares are subject to vesting conditions.

What Was Disclosed

Royalty Pharma plc officer Christopher Hite disclosed the acquisition of 7,122 Class A Ordinary Shares at $0 through an Equity Performance Award settlement on November 4, 2026, along with details of his broader indirect beneficial ownership in the company.